| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.003 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.17 | 0.003 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.005 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.14 | 0.008 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |